Management of cardiopulmonary bypass in patients with ischemic and hemorrhagic strokes in surgery for active infective endocarditis

被引:0
作者
Yamazato, Takahiro [1 ]
Munakata, Hiroshi [1 ]
Okita, Yutaka [2 ]
机构
[1] Okinawa Nanbu Prefectural Med Ctr & Childrens Med, Dept Cardiovasc Surg, Haebaru, Okinawa 9011193, Japan
[2] Takatsuki Gen Hosp, Dept Cardiovasc Surg, Takatsuki, Osaka, Japan
关键词
Cardiopulmonary bypass; Nafamostat mesylate; Low-dose heparin; Intracranial hemorrhage; Neurological complication; NAFAMOSTAT MESILATE; CARDIAC-SURGERY; CEREBRAL COMPLICATIONS; NAFAMSTAT MESILATE; ANTICOAGULATION; HEPARIN; ASSOCIATION; PLATELETS; FUT-175; IMPACT;
D O I
10.1007/s12055-023-01642-0
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Stroke and intracranial hemorrhage (ICH) are serious complications that are difficult to manage during surgery for active infectious endocarditis (AIE). Relevant society guidelines still recommend delaying the cardiac surgery for AIE with ICH for 4 weeks. Some early studies indicated that the mortality rate decreases when cardiac surgery for ICH is delayed. In contrast, some reported that surgical intervention should not be delayed if an early operation is demanded, even in patients with ICH. The current literature on early vs. late surgery for infectious endocarditis (IE) with ICH is conflicting. Changing the cardiopulmonary bypass (CPB) strategy might be necessary to improve the surgical outcomes of IE with ICH. Some studies reported that cardiac surgery using nafamostat mesylate (NM) as an alternative anticoagulant during CPB was performed successfully. The combination of NM and low-dose heparin was beneficial for early surgery in patients with AIE complicated by cerebral infarction and ICH, without worsening cerebral lesions. In this report, we review and discuss the management of CPB in patients with ischemic and hemorrhagic stroke during surgery for AIE.
引用
收藏
页码:61 / 68
页数:8
相关论文
共 45 条
[1]   Nafamostat prevents hypothermia and improves survival time after administration of lipopolysaccharide in a mouse surgical model [J].
Adachi, Yushi U. ;
Obata, Yukako ;
Suzuki, Katsumi ;
Katoh, Hiromi ;
Itagaki, Taiga ;
Doi, Matsuyuki ;
Sato, Shigehito .
JOURNAL OF ANESTHESIA, 2009, 23 (04) :624-627
[2]   PHARMACOLOGICAL STUDIES OF FUT-175, NAFAMSTAT MESILATE .1. INHIBITION OF PROTEASE ACTIVITY IN INVITRO AND INVIVO EXPERIMENTS [J].
AOYAMA, T ;
INO, Y ;
OZEKI, M ;
ODA, M ;
SATO, T ;
KOSHIYAMA, Y ;
SUZUKI, S ;
FUJITA, M .
JAPANESE JOURNAL OF PHARMACOLOGY, 1984, 35 (03) :203-227
[3]   Indications and optimal timing for surgery in infective endocarditis [J].
Delahaye, F ;
Célard, M ;
Roth, O ;
de Gevigney, G .
HEART, 2004, 90 (06) :618-620
[4]   Response of kaolin ACT to heparin: Evaluation with an automated assay and higher heparin doses [J].
Despotis, GJ ;
Alsoufiev, AL ;
Spitznagel, E ;
Goodnough, LT ;
Lappas, DG .
ANNALS OF THORACIC SURGERY, 1996, 61 (03) :795-799
[5]   Anticoagulation monitoring during cardiac surgery - A review of current and emerging techniques [J].
Despotis, GJ ;
Gravlee, G ;
Filos, K ;
Levy, J .
ANESTHESIOLOGY, 1999, 91 (04) :1122-1151
[6]   Preventing thrombosis in a COVID-19 patient by combined therapy with nafamostat and heparin during extracorporeal membrane oxygenation [J].
Doi, Shunichi ;
Akashi, Yoshihiro J. ;
Takita, Mumon ;
Yoshida, Hideki ;
Morikawa, Daiki ;
Ishibashi, Yuki ;
Higuma, Takumi ;
Fujitani, Shigeki .
ACUTE MEDICINE & SURGERY, 2020, 7 (01)
[7]   SURGICAL-MANAGEMENT OF INFECTIVE ENDOCARDITIS ASSOCIATED WITH CEREBRAL COMPLICATIONS - MULTICENTER RETROSPECTIVE STUDY IN JAPAN [J].
EISHI, K ;
KAWAZOE, K ;
KURIYAMA, Y ;
KITOH, Y ;
KAWASHIMA, Y ;
OMAE, T .
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 1995, 110 (06) :1745-1755
[8]   NEW SYNTHETIC INHIBITORS OF CHYMOTRYPSIN [J].
FUJII, S ;
YOKOYAMA, T ;
IKEGAYA, K ;
YOKOO, N .
JOURNAL OF BIOCHEMISTRY, 1984, 95 (02) :319-322
[9]  
Fukata Y., 1994, IRYO, V48, P196
[10]  
Furuta Akihisa, 2020, Kyobu Geka, V73, P905